Abbott Spins Off Nutrition and Trims Its Sales Guide as CGM Pricing Bites, but a 7% Quarter Keeps the Thesis Alive

Results vs. Consensus

Q3 2026 Scorecard

Year-Over-Year Comparisons

Quarter-Over-Quarter Comparisons

Quality of Result

Revenue: The reported +14.5% is mostly the Exact Sciences consolidation (Cancer Diagnostics added $968M against nothing a year ago); the comparable +7.0%, which folds Exact Sciences into both years and strips a 0.4% FX headwind, is the number that matters. It was the best comparable print of 2026 and a 220bp step-up from Q2, and the composition was broad: Medical Devices +7.8%, Established Pharmaceuticals +8.4%, Diagnostics +6.4% and Nutrition +4.9%. U.S. comparable growth (+7.9%) outpaced international (+6.4%). The sales line beat a consensus that sat near $12.99B by roughly $23M. The one soft spot was CGM: Diabetes Care grew 6.7% and CGM 7.7%, a deceleration from 9.5% in Q2. Management described the quarter as two businesses ahead of plan, one on plan and one behind.

Margins: Adjusted gross margin of 57.2% expanded 140bp year over year on legacy-portfolio mix, the accretive Exact Sciences addition and the margin programs. It fell 80bp from Q2's 58.0%, which we read as normal quarter-to-quarter mix rather than a reversal. Adjusted operating margin of 23.4% rose 40bp: the gross-margin gain was partly reinvested, with R&D up 50bp to 6.9% of sales and SG&A up 50bp to 26.9%, the latter now including Exact Sciences' commercial organization. Management also said it can absorb the coming CGM price concessions through manufacturing cost programs, which is the claim to test over the next few quarters.

EPS: The $1.42 grew 9.2% and matched both the consensus and the midpoint of the $1.38–$1.46 guide. Below the operating line, net interest expense rose to $297M from $44M on the acquisition debt, while a lower adjusted tax rate (15.2% vs. 16.5%) and a 0.6% lower share count helped. The GAAP figure of $0.53 fell 43.6% because of $841M of intangible amortization and roughly $670M of legal settlements tied to the Gill case and the NEC claims of about 2,000 additional infants. The settlement is excluded from adjusted EPS, but it is real cash and we treat it as such in the litigation discussion below.

Segment Performance

Medical Devices: EP Leads, CGM Slows, Structural Heart Still Split

Electrophysiology: The Ablation Ramp Is Real, and So Is the LAA Pause

EP grew 15.5% comparable to $873M, an acceleration from 13.4% in Q2. In the U.S. the line grew 18.1%, and management said U.S. growth exceeded 20% excluding the left atrial appendage (LAA) devices that moved into EP at the start of 2026. The driver is the Volt pulsed field ablation (PFA) catheter, which moved from a limited to a full U.S. market release in mid-August, with momentum building into September. Europe EP grew 25%. FDA approval of the TactiFlex Duo dual-energy catheter came earlier than expected in September, and Volt launches in Japan in Q4.

"This performance was driven by increasing adoption of our new Volt PFA catheter, with momentum accelerating in September following the transition to a full U.S. market release in mid-August." — Robert Ford, Chairman & CEO

Assessment: The ablation business is doing what the thesis needs, and the U.S. ex-LAA rate above 20% is the cleanest evidence yet that Abbott is taking PFA share. The offset is the LAA franchise, which management now expects to cost about 5 points of EP growth in Q4 (roughly 20% instead of roughly 25%). That is a timing problem tied to a product transition, not a share problem in ablation, but it is one of the two reasons the full-year sales guide came down.

Diabetes Care: CGM Decelerates and the Outlook Steps Down

Diabetes Care grew 6.7% comparable to $2,185M, with CGM up 7.7% comparable (7.3% reported). The U.S. held up at +9.4%; international slowed to +4.9%. The quarter was a step down from Q2's 9.5% CGM growth, and the outlook stepped down further: management now expects diabetes care to grow at a low-to-mid-single-digit rate in Q4 and probably for the next few quarters, down from the high-single-digit view it gave in July, citing slower penetration of the type-2 population without broader reimbursement and international price adjustments to defend share. The offsets are real but sit in 2027: the Libre Duo glucose-ketone sensor won FDA approval in August and launches in the U.S. in December, and a significant U.S. payer formulary coverage decision flips in Abbott's favor on January 1.

"This marks the first time that people with diabetes will be able to monitor ketones without the need for traditional blood or urine tests, and we expect to launch this new sensor in the U.S. in December." — Robert Ford, Chairman & CEO

Assessment: This is the most important negative in the print. In July we called 9.5% CGM growth "a plateau before a step-up." Three months later the plateau is lower, and management has told us it will spend price internationally to protect volume. A franchise with 50–70% share in its major international markets choosing to trade price for share is a rational defense, but it is also an admission that the category is becoming more competitive faster than our thesis allowed. We move the Libre pillar to at risk.

Rhythm Management, Vascular, Heart Failure and Structural Heart

Rhythm Management grew 10.0% on adoption of the AVEIR leadless pacemaker in both single- and dual-chamber settings. Vascular grew 5.7%, sustaining the mid-single-digit pace that management contrasts with the negative-to-flat business of a few years ago, and coronary intravascular lithotripsy (IVL) has been filed for approval, with a decision expected in the first half of 2027. Heart Failure slowed to 6.0% on a 1.6% international decline. Structural Heart grew 6.9% overall on 13.5% international growth, but the U.S. business fell 2.3% comparable, and the call offered no update on the U.S. recovery that management promised in July for Q4.

"In rhythm management, sales grew 10%, driven by increased adoption of AVEIR across both single and dual-chamber segments of the pacemaker market." — Robert Ford, Chairman & CEO

Assessment: The cardiovascular breadth remains intact: five of the six cardio and neuro lines grew at mid-single digits or better, and the pipeline (Amulet 360, coronary IVL, conduction-system leadless pacing, the Cephea mitral valve, balloon-expandable TAVR) is deep. The U.S. Structural Heart line is the exception, and it is now two quarters behind the July timeline with no public update. Neuromodulation (−1.1%) remains the soft spot.

Diagnostics: Core Lab Broadens, Cancer Diagnostics Absorbs a Cyber Event

Diagnostics grew 6.4% comparable, more than double Q2's 2.9%. Core Laboratory accelerated to 5.4% from 3.2%, with growth across the U.S., Europe, Japan and Latin America, and international Core Lab grew 5.1%, which suggests the China volume-based procurement drag that dominated 2025 has largely washed through. Rapid and Molecular turned slightly positive after the weak respiratory season ended. Cancer Diagnostics grew 13.8% on mid-teens Cologuard, with contributions from precision oncology and the international business, but came in below the 15–15.5% the Street had modelled. Management blamed most of the gap on a July cybersecurity incident that caused some health systems to cut connectivity for 7 to 10 days.

"In cancer diagnostics, sales growth of 14% was driven by Cologuard and contributions to growth from our precision oncology and international businesses." — Robert Ford, Chairman & CEO

Assessment: The diagnostics recovery we have tracked since Q3 2025 is now visible in the reported number, not just the U.S. sub-line, and our original bear point on diagnostics can be considered contained. Cancer Diagnostics missed the Street by about a point and a half, but the cause was operational and short, and the business's operating margin has moved to the high teens from roughly breakeven before the acquisition. The September launch of the SimpleScreen blood-based colorectal test adds a higher-priced product that management positions as an on-ramp rather than a replacement for Cologuard.

Nutrition: Positive a Quarter Early, and Now Leaving

Nutrition grew 4.9% comparable, its first positive quarter of 2026 (the nine-month figure is still −2.1%), with growth in all four categories. U.S. Pediatric led at +11.0% on the WIC contract wins that took effect earlier this year, and U.S. Adult grew 3.5% as Ensure retail consumption kept improving. Sales rose $118M from Q2. The new whole-milk Similac ready-to-feed formula launched in August.

"In pediatric nutrition, sales grew 9%, led by growth of 11% in the U.S." — Robert Ford, Chairman & CEO

Assessment: We asked for a positive comparable print by Q4. It arrived in Q3, which clears the operating version of our nutrition bear point. The strategic version is now being resolved by a different route: Abbott is spinning the business off. The return to growth matters for valuation because it lets the spin launch with a growing business, which is the "position of strength" management emphasized.

Established Pharmaceuticals: The Steady Compounder

EPD grew 8.4% comparable to $1,614M (+6.8% reported, with a 1.6-point FX drag). Key Emerging Markets grew 10.9% comparable, with double-digit growth in India and several markets across Latin America, Asia and the Middle East; the rest of the portfolio grew 1.6%.

"Growth in the quarter was broad-based across geographies and therapeutic areas, and this included double-digit growth in several countries across Asia, Latin America, and the Middle East, highlighting the strong and durable demand that has long been a hallmark of this business." — Robert Ford, Chairman & CEO

Assessment: No change. EPD keeps compounding at the high single digits management describes as its five-year pattern, and the biosimilar opportunity in emerging markets that management raised on the call is a future addition. After the spin, EPD becomes a larger share of the remaining company, which slightly raises Abbott's emerging-market exposure.

Key Topics & Management Commentary

Overall Management Tone: Assertive on strategy, more candid than usual on the top line. Management led with the separation and defended it at length, framed the guide cut as two identifiable, temporary problems, and conceded, unusually for this team, that its sales delivery this year had fallen short. The tone on 2027 shifted from July's acceleration narrative to deliberate under-promising, and management was notably non-committal on the two questions investors care most about: where the NEC liability will sit and whether double-digit EPS growth survives into next year.

1. The Nutrition Separation: Strategy First, Arithmetic Second

Abbott announced its intention to separate its Nutrition business into an independent public company through a tax-free distribution, targeted for completion by the end of 2027. The new company will have about $8.5B of annual sales, 16,000 employees and 14 plants, with brands including Similac, PediaSure, Ensure, Glucerna and Pedialyte, and will be run by Daniel Salvadori, currently head of Established Pharmaceuticals and Nutrition. Management's stated rationale was strategic rather than financial: nutrition has shifted from a healthcare market shaped by clinicians to a consumer market shaped by wellness trends and retail execution, and that business needs a different investment model than Abbott's device and diagnostics engines.

"What was once predominantly viewed as a healthcare market, almost exclusively shaped by healthcare professionals, has increasingly become a market shaped by changing consumer preferences, wellness trends, and retail execution." — Robert Ford, Chairman & CEO

On timing, management argued it is separating from strength: the business returned to growth this quarter, the pipeline has fresh launches, and the Exact Sciences integration is far enough along to free organizational bandwidth. A sale was ruled out on tax grounds (Abbott has owned the business since the 1960s) and because the timeline would not be in Abbott's control.

Assessment: This is the right structural decision and one we have implicitly argued for: nutrition has been the most volatile segment through the 2022 recall, the 2025 price resets and the NEC litigation, and it has diluted the growth and margin profile of a company that is otherwise a medical technology and diagnostics business. A spin does not create value by itself, but it removes the discount that a slower, litigation-exposed consumer business imposes on the rest of the portfolio. The 14-month timeline means the benefit is a 2027 story, not a 2026 one.

2. What Remains: A Faster, Higher-Margin Abbott

The remaining company will have about $42B of sales and roughly 106,000 employees. Management gave the first quantification of what removing nutrition does to today's profile: sales growth 50–100bp faster, gross margin more than 200bp higher and operating margin about 100bp higher. The new company will raise debt and pass part of the proceeds to Abbott, and the two companies' combined dividend will equal Abbott's dividend at separation. One-time separation costs will be excluded from adjusted earnings, and management said the spin will not affect the 2026 guidance or the 2027 guidance coming in January.

"Excluding the current profile of the nutrition business from the current profile of the Abbott portfolio, we would expect sales growth to accelerate by 50 to 100 basis points, gross margin as a percent of sales to increase by more than 200 basis points, and an operating margin as a percent of sales to increase by approximately 100 basis points." — Philip Boudreau, EVP Finance & CFO

Assessment: The numbers are what the sum-of-the-parts argument needs: a remaining company growing near 7% organically with a gross margin above 59% on today's figures is closer to the large-cap medtech peer group than to a diversified conglomerate. The open items are stranded costs, which were not quantified, and the size of the debt-funded distribution back to Abbott, which will determine how much balance-sheet flexibility the remaining company keeps. Neither changes the direction of the trade.

3. The Sales Guide Cut: Two Businesses, Not a Broad Slowdown

Abbott cut its 2026 comparable sales growth guide to about 6% from 6.5–7.5%. With the first nine months at +5.2%, the new figure implies Q4 comparable growth just above 8%. Under the old midpoint, Q4 would have needed roughly 12%; we flagged in July that the old guide required about 9.5% growth across the second half, and the second half now looks closer to 7.6%. Management attributed the gap entirely to EP (the LAA pause) and diabetes care (CGM pricing and type-2 penetration), and described both as temporary adjustments rather than permanent changes to the growth rate.

"Yeah, listen, our Q3 growth was in line with the expectation of 7%. We had the normal puts and takes ... We had 2 businesses that beat expectations, one business that met expectations, and then one business that missed expectations." — Robert Ford, Chairman & CEO

The EPS guide absorbed the change: the full-year range tightened to $5.50–$5.55 around an unchanged $5.525 midpoint, and Q4 EPS was guided to $1.62–$1.67.

Assessment: We were right that the full-year sales guide was the number at risk, and we should own that the July debate ("can the H2 ramp deliver") resolved against the bull side on the sales line. What keeps this a trim rather than a break is the shape: Q3 accelerated as promised, Q4 is still guided to accelerate again to about 8%, earnings were protected, and the shortfall is concentrated in two named businesses with named causes. A broad deceleration would have been far worse for the thesis than two isolated misses.

4. CGM: Trading Price for Share Abroad

The CGM outlook was the most consequential disclosure on the call. Management now expects diabetes care, where CGM is the bulk of sales, to grow at a low-to-mid-single-digit rate in Q4 and probably for the next few quarters, down from the high-single-digit view it gave in July. Two factors drive it: slower penetration of the type-2 non-insulin population while broader Medicare coverage is pending, and price adjustments in international markets, where Abbott holds 50–70% share in the major countries and competition is intensifying. Management was explicit that it will not match competitors' prices but will adjust enough to avoid losing share, and expects to offset the margin effect through manufacturing cost programs.

"If I look into Q4 right now, and probably for the next few quarters, I expect that growth rate to be in that low to mid-single range." — Robert Ford, Chairman & CEO

"I think it would be a strategic mistake for us to lose market share based on price in these international markets. We're not having to match the pricing ... but I think we're having to adjust a little bit here as we go through this." — Robert Ford, Chairman & CEO

Management listed the counterweights: the Libre Duo launch in December, a significant U.S. payer formulary change in Abbott's favor on January 1, and type-2 non-insulin Medicare coverage, which it is not forecasting and not building into 2027 plans. It added that it would not be surprised to beat the low-to-mid-single-digit range next year.

Assessment: This changes the shape of the Libre pillar. Our thesis assumed CGM was a structurally double-digit grower moving between reimbursement catalysts; management is now telling us international pricing will cap growth for several quarters even before a catalyst arrives. Defending share at a modest price cost is the right choice for a 50–70% share leader, and the U.S. (+9.4%) is not the problem. But the CGM growth premium was a large part of why we argued Abbott deserved a higher multiple, and that premium is now unproven until the pricing resets are behind it.

5. Electrophysiology: Volt Full Release, TactiFlex Duo, and an LAA Air Pocket

EP grew 15.5%, mid-to-high teens excluding LAA, with U.S. ex-LAA growth above 20% and Europe up 25%. The drag is LAA closure. The category slowed earlier this year for a competitor, and Abbott felt it a quarter or two later; then U.S. orders slowed almost immediately after Amulet 360 received its CE Mark, as accounts appear to be waiting for the next-generation device in the U.S. Management expects this to be the last quarter of the drag and cut its Q4 EP expectation to about 20% from about 25%, while insisting it is still gaining share in ablation.

"But what was interesting is as soon as we got CE Mark for the new LAA device, there was almost like an immediate slowdown in orders here in the U.S. as I think accounts are waiting for the new product." — Robert Ford, Chairman & CEO

Q4 brings a full quarter of Volt in full U.S. release, a short limited release then broad launch of TactiFlex Duo, and the Volt launch in Japan, which management expects to turn Japan from a headwind into a tailwind. Amulet 360 pivotal data were set for presentation at TCT.

Assessment: The ablation story strengthened this quarter: an accelerating PFA franchise in the U.S., a second PFA-capable catheter approved early, and Japan opening. The LAA pause is a classic product-transition air pocket that should reverse once Amulet 360 reaches the U.S., although the timing of that approval was not given. We keep EP as the strongest growth line in the portfolio and treat the Q4 trim as timing.

6. Nutrition Returns to Growth on the Way Out

Nutrition grew 4.9% with all four categories (U.S. and international, pediatric and adult) positive, and management emphasized that the growth now rests on a more sustainable mix of volume and price. It also said its volume growth this quarter and its projection for the next few quarters are well above the peer set.

"Turning to nutrition, sales grew 5%, reflecting broad-based growth across all 4 categories: U.S. pediatric, international pediatric, U.S. adult, and international adult." — Robert Ford, Chairman & CEO

Assessment: The timing is not a coincidence. A spin is easier to execute and value when the asset is growing, and the price resets of late 2025 have now produced the volume response that management promised. For the remaining company the point is moot after 2027; for the next five quarters, a growing nutrition segment helps the consolidated top line rather than drags on it.

7. Cancer Diagnostics: A Cyber Blip, a Blood Test, and Margins in the High Teens

Cancer Diagnostics grew 13.8% against a Street figure near 15%. Management attributed about a point of growth to a July cybersecurity event during which some health systems disconnected from Abbott's ordering systems for 7 to 10 days and reverted to fax and email. Cologuard grew mid-teens with growth in new users, rescreens, international and care-gap programs, though management conceded care-gap timing is harder to forecast because payers and health systems control when orders go out. The SimpleScreen blood-based screening test, developed with a partner, began promotion on September 30 at a higher average selling price but a different margin profile. Management also expects the Cologuard Plus reimbursement rate, which is still being set by CMS, not to decline.

"Those blips, which lasted about 7-10 days, that cost us about a point of growth." — Robert Ford, Chairman & CEO

"We're exiting the Q3 with an operating margin profile in the high teens already with this business." — Robert Ford, Chairman & CEO

Assessment: The top line slipped modestly for an identifiable, non-recurring reason, and the profitability turnaround is faster than we expected: an operating margin in the high teens six months after closing a deal for a business that was barely profitable is the integration case working. The Cologuard Plus rate is the risk to watch, but management's language ("very hard to imagine" a cut) is as firm as it gets without a final decision.

8. Margins: Expansion Through the Mix, Reinvested in the Pipeline

Adjusted gross margin rose 140bp to 57.2% and adjusted operating margin rose 40bp to 23.4%. Management attributed the gross-margin gain to legacy-portfolio mix, the addition of Exact Sciences, and operational improvements. The difference between gross and operating expansion went into R&D (6.9% of sales) and SG&A (26.9%).

"Regarding other aspects of the P&L, the adjusted gross margin profile was 57.2% of sales, representing an increase of 140 basis points compared to the prior year." — Philip Boudreau, EVP Finance & CFO

Assessment: The margin pillar holds. The more important margin question is forward: CGM price concessions are a direct hit to the highest-margin consumable in the portfolio, and management claims cost programs will offset them. If that offset works, the EPS algorithm is protected even with slower CGM growth; if it does not, 2027 EPS is where we would see it.

9. 2027: A Conservative Starting Point by Design

Management previewed 2027 more explicitly than usual. The initial sales guide will likely look "pretty similar to this year," roughly 6%, even though management said it expects the growth rate to accelerate given carryover launches, new launches and easier first-half comparisons. The stated reason was credibility: Abbott has met or beaten its EPS target every quarter for six years, but its top-line record this year has been inconsistent. On EPS, management promised growth, gross-margin expansion, continued pipeline investment and a higher dividend, but declined to give a number.

"As it relates to our top line, I think we've been very good, but I'd say the track record here in the last couple of quarters, or especially during this year, has been a little bit more inconsistent, let's call it like that, and we've fallen short from some of the expectations." — Robert Ford, Chairman & CEO

Assessment: Resetting to a beatable number is the right move for a management team that has cut a sales guide, and it is the main reason we expect the stock to need time rather than a single catalyst. The cost is near-term: a ~6% starting point is below the 7%+ organic algorithm our base case assumed, and the absence of a double-digit EPS commitment leaves our ~$6.00 2027 estimate (about 8.6% growth) as a reasonable middle rather than a conservative floor.

10. NEC Litigation: A Large Settlement and an Open Allocation Question

In Q3 Abbott resolved the Gill case and, in August, settled the NEC claims of about 2,000 additional infants, recording roughly $670M of legal settlements as a specified item. Year to date, legal settlements total about $1.07B, including about $400M to resolve Justice Department investigations and a related civil lawsuit. Management maintained its position on the products' safety and efficacy, said the litigation environment is shifting in its favor after federal MDL wins, and said resolving the cases is not a precondition for the spin. It did not say which company will carry the liability.

"Actually pretty clear that we don't need to fully resolve the litigation matters. It's not a prerequisite for completing the separation." — Robert Ford, Chairman & CEO

Assessment: The settlement converts part of an unquantified tail into a known, absorbed cost, which is constructive. But the allocation of the remaining liability is now the most important unanswered question in the spin. If it travels with the nutrition company, the remaining Abbott is a clean medtech and diagnostics story; if it stays behind, the spin removes the business but not the overhang. We keep the NEC bear point contained, with the allocation decision as the new watch item.

11. The Macro Tell Holds: Testing Volumes Stay Durable

In July, management used test-volume data from thousands of connected instruments to argue that U.S. procedure demand was not slowing. This quarter it repeated the read, and Core Lab growth of 5.4% with balanced geographic growth supported it.

"During the third quarter, our testing data continued to support that view, with testing demand remaining healthy and at durable levels." — Robert Ford, Chairman & CEO

Assessment: For a diversified healthcare company, stable underlying utilization means the guide cut is about Abbott-specific product cycles and pricing, not demand. That distinction matters: product-cycle problems fix themselves with launches, while a demand problem would affect every segment at once.

12. Pipeline Spend and Balance-Sheet Capacity

R&D spending will cross $3B this year, up from about $1.7–$1.8B before COVID, and will rise again in 2027. Management named the leadless conduction-system pacing trial, the Cephea mitral replacement valve, balloon-expandable TAVR, IVL, neuromodulation, a lactate sensor on the Libre platform and an MRD cancer test (with data at ESMO) as programs it is funding. On capital, net debt to EBITDA is about 2x, the last large maturities from the St. Jude and Alere deals are paid this year, buybacks are possible, and M&A will lean to tuck-ins.

"If you look at the R&D spend for Abbott pre-COVID, we were averaging around $1.7 billion, $1.8 billion. We're crossing $3 billion this year." — Robert Ford, Chairman & CEO

Assessment: Abbott is funding growth through a soft patch rather than cutting R&D to protect EPS, which is the behavior of a franchise that expects the product cycle to pay off. Combined with ~2x leverage and the debt-funded distribution from the nutrition spin, the remaining company should have room for buybacks at a below-average multiple.

Guidance & Outlook

The guidance story has two halves that point in different directions. On earnings, Abbott held its full-year midpoint and guided Q4 EPS to $1.62–$1.67, up about 9.7% at the midpoint from $1.50 a year ago, which puts full-year adjusted EPS growth at roughly 7.3% including the Exact Sciences dilution. On sales, the full-year range came down and management deliberately framed 2027 as a beatable starting point.

Implied Q4 ramp: Nine-month comparable growth was 5.2%. Reaching about 6% for the year requires Q4 comparable growth just above 8%, which management confirmed, an acceleration from Q3's 7.0%. The drivers are a full quarter of Volt in full U.S. release plus the TactiFlex Duo and Japan launches in EP, continued nutrition growth against an easy comparison (the segment fell sharply in Q4 2025), Cancer Diagnostics care-gap seasonality, and Core Lab momentum. The drags are CGM at low-to-mid single digits and the LAA pause.

Street at: The $1.62–$1.67 Q4 range brackets the ~$1.65 pre-print consensus, and the $5.525 full-year midpoint sits on the ~$5.53 Street figure, so earnings estimates should hold. Sales estimates for Q4 and 2027 come down, particularly for diabetes and EP.

Guidance style: Conservative by intent. Management said in plain terms that it will start 2027 below what it believes the business can deliver so it can raise through the year. That is a credibility reset, and for a stock that has fallen on every sales disappointment this year, it is the right one.

Analyst Q&A Highlights

Why Spin, Why Now, and Why Not Sell

The opening question went straight to the separation: its strategic rationale, the timing and the choice of a spin over a sale. Management spent most of its answer on the strategic case for a standalone healthy-nutrition company and on sequencing after the Exact Sciences integration, then ruled out a sale on tax and timing grounds.

Q: "Maybe you could run through the strategic rationale, why now, why spin versus sell, and any other important points you want to highlight for us."
— Robert Marcus, JPMorgan

A: "A sale of a business like this, as I said, we've been in this business since the 1960s. So you think about the sale, the sale's going to come with an obvious tax implication there. And then a timeline that is not necessarily entirely within our control here."
— Robert Ford, Chairman & CEO

Assessment: A low tax basis after six decades makes a sale expensive, so the spin is the value-maximizing route. Management was emphatic that it is not looking at a sale, which closes off the near-term cash-proceeds scenario some investors may have hoped for and puts the value creation in the hands of the two companies' future multiples.

Where the NEC Liability Sits After the Separation

A follow-up asked management to confirm that the NEC liability will stay with Abbott, as has been common in other spins. Management declined to confirm either way, said resolution is not a prerequisite for the separation, and promised details later.

Q: "Just confirm, please, that the NEC liability will remain with Abbott."
— Larry Biegelsen, Wells Fargo

A: "I'll provide more details of that as we progress in terms of exactly where the liability will sit. But for me, both companies are going to be super well capitalized to be able to deal with that."
— Robert Ford, Chairman & CEO

Assessment: The non-answer is the answer for now. Management did not accept the premise that the liability stays with Abbott, which leaves open an allocation to the nutrition company. Until the Form 10 sets this out, the market will apply an overhang discount to whichever entity it assumes carries the claims.

The Drivers of the Guide Cut and What It Means for 2027

The same analyst then pressed on the drivers of the full-year sales cut and the read-through to 2027. Management walked through the EP and diabetes explanations in detail and then previewed a deliberately conservative 2027 sales framework.

Q: "The revenue guidance reduction, I think to 6% this year implies about 8% for Q4. What was the driver or drivers of the revenue reduction and implications for next year?"
— Larry Biegelsen, Wells Fargo

A: "I'm not going to give an official guidance here before our January's call, but high level, I'd say forecasting sales to be, as we come out of the gate, pretty similar to this year."
— Robert Ford, Chairman & CEO

Assessment: The most market-relevant exchange on the call. The candid admission on top-line consistency and the decision to start 2027 low are credibility-building, but they also cap how much the stock can re-rate before January, and arguably before the first 2027 raise.

How the Pipeline Compares With the Past

A question asked management to rate the forward pipeline against prior periods and to name programs the market under-appreciates. Management declined to rank programs but described R&D spend rising past $3B and singled out the Cephea mitral replacement valve and the leadless conduction-system pacing program.

Q: "A, how do you feel about the forward pipeline today compared to the forward pipeline in the past? How would you rate it?"
— Patrick Wood, UBS

A: "You can tell sometimes when an innovation is good, and it'll compete well, and you can tell when a KOL tells you that this is really going to be a game changer, and it's going to change kind of the standard. I think our Cephea program's going to do that."
— Robert Ford, Chairman & CEO

Assessment: The pipeline is broad, and management's willingness to keep raising R&D through a guide cut is consistent with the long-cycle thesis. The Cephea comment is the most specific conviction signal on the call, but it is a 2028-and-beyond contributor, not a fix for the next four quarters.

Why Cancer Diagnostics Fell Short of the Mid-Teens

A question noted that Cancer Diagnostics growth came in below the hoped-for step-up into the mid-teens and asked about Cologuard, the rest of the business and the blood-test partner. Management blamed the July cyber incident for about a point, described Cologuard as still accelerating, and positioned the blood test as a complement rather than a preferred test.

Q: "It looks like you did a little bit better this quarter, but I know you're hoping for a step up into the mid-teens. Could you just touch on the dynamics with Cologuard, the rest of the business, and maybe give us some thoughts on Freenome?"
— Matt Taylor, Jefferies

A: "I'd say the biggest driver of that delta versus expectation there was the cybersecurity event that we had in July. That caused us to lose a little bit of momentum."
— Robert Ford, Chairman & CEO

Assessment: A credible, specific and non-recurring explanation. The more durable takeaways from the answer were the high-teens operating margin and management's view that stool-based screening remains the standard of care, which supports Cologuard's pricing and rescreen economics even as blood tests enter the market.

Whether Double-Digit EPS Growth Survives Into 2027

A question asked directly whether investors should still model double-digit EPS growth for 2027. Management would not give a number, listing EPS growth, gross-margin expansion and cash flow as commitments without quantifying them.

Q: "Thanks for the color on top line, but should we still be aiming for double-digit EPS growth?"
— Vijay Kumar, Evercore ISI

A: "But like I said, we're going to have EPS growth, we're going to have gross margin expansion, we're going to have all the things that you would expect, and probably leave the actual specific guidance range for EPS and all other elements, cash flow, all of that, we'll leave that to January."
— Robert Ford, Chairman & CEO

Assessment: A dodge, and a telling one. A management team confident in double-digit growth would have said so, as this one did in prior years. We read it as high-single-digit EPS growth being the more likely 2027 starting point, which is how we now model it.

Readouts at TCT and the Timing of Amulet 360 and Coronary IVL

A question asked about the Amulet 360 and coronary IVL pivotal readouts scheduled for TCT, how quickly the products can launch, and when the LAA market stabilizes. Management declined to preview the data, said the coronary IVL device has been filed with approval expected in the first half of 2027, and declined to forecast LAA share.

Q: "At TCT in a couple of weeks, we've got Amulet 360 pivotal data and coronary IVL pivotal data. Just curious anything you'd say on that, and then how quickly those products can launch."
— Travis Steed, BofA Securities

A: "We filed, at least for the coronary side, we filed for approval. I don't know exactly when, but I know we're expecting it sometime in the first half, and maybe we might surprise on the earlier side there."
— Robert Ford, Chairman & CEO

Assessment: IVL gives Vascular a new growth leg in a $1B-plus market that Abbott entered through the CSI acquisition rather than a large deal. The absence of a U.S. timeline for Amulet 360 matters more, because the LAA order pause lasts until U.S. accounts can buy the new device.

Type-2 Medicare Coverage and M&A Capacity After the Spin

The final question asked about Medicare reimbursement for CGM in non-insulin type-2 patients and whether the spin constrains M&A. Management again declined to forecast the CMS decision and said it is not in its plans for next year, and said the spin does not limit M&A, which will lean toward tuck-ins with net debt to EBITDA around 2x.

Q: "Can you comment on potential reimbursement from CMS for non-intensive type 2 for CGM use?"
— Joanne Wuensch, Citi

A: "I am not going to say that it is embedded in a forecast for next year. Right now, what I can say is I'm not really factoring it in."
— Robert Ford, Chairman & CEO

Assessment: Keeping the type-2 decision out of the 2027 plan is consistent with the conservative reset, and it means a favorable decision would be pure upside to both the CGM line and the guide. It is also the clearest single catalyst that could move the Libre pillar back to on track.

What They're NOT Saying

1. Where the NEC liability will sit: Asked directly, management would only say details will come later and that both companies will be well capitalized. This allocation is the single largest determinant of how the market values each company after the spin.
2. A 2027 EPS growth rate: Management gave a sales starting point but declined to say whether EPS growth will be double-digit, deferring everything to January.
3. The size of the CGM price concessions: Management said it will "adjust a little bit" internationally and offset the margin effect through cost programs, but gave no magnitude, no list of markets and no named competitor, so the earnings effect cannot yet be modelled with confidence.
4. The nutrition company's standalone profitability and the costs of separating it: Management gave the deltas for the remaining company but not the nutrition business's own margin, the stranded costs left at Abbott, the size of the one-time charges, the debt the new company will raise or the distribution ratio.
5. U.S. Structural Heart: The business fell 2.3% comparable in the U.S., and Structural Heart was not discussed on the call beyond pipeline mentions of the Cephea mitral valve and balloon-expandable TAVR. The July commitment to mid-to-high-single-digit growth by Q4 was neither repeated nor withdrawn.
6. A U.S. timeline for Amulet 360: The LAA order pause in the U.S. is tied to accounts waiting for the new device, yet management gave no U.S. approval timing, which leaves the end of the pause undated.
7. China: After a year in which China volume-based procurement was the central diagnostics debate, neither China nor VBP was mentioned on the call. The 5.1% international Core Lab growth suggests the drag has faded, but management did not confirm it.

Market Reaction

• Pre-print setup: ABT closed at $102.45 on October 20, down 18.2% year to date against the S&P 500's 12.7% gain and down 19.7% over the trailing twelve months, but up about 3.7% from the $98.83 close after the Q2 print. The stock slipped 1.5% in the session before the release and was down 0.5% over the trailing 30 days, inside a 52-week closing range of $82.56–$130.59.
• Reaction day (October 21, before-the-open release): Shares were indicated down about 1.4% before the open and opened at $101.31 (−1.1%). They then swung across a $97.67–$106.35 range, from 4.7% down to 3.8% up, and closed at $100.51, down 1.9% ($1.94), while the S&P 500 rose 0.6%.
• Volume: 22.9M shares against a 9.2M 30-day average, a 2.5x spike.
• Following sessions: ABT rose 2.0% to $102.51 on October 22 and 1.2% to $103.70 on October 23. Over the three sessions from the pre-print close, the stock gained 1.2% while the S&P 500 fell 1.2%.

Spin versus guide, a tug of war: The reaction day's $8.68 intraday range, roughly 8.5% of the pre-print price, shows the market weighing two things at once. The separation is a value-creation event investors have long debated for a conglomerate whose consumer segment diluted its medtech profile, and the stock's early high reflected that. The sales guide cut, and especially the CGM outlook, pulled it the other way, because CGM growth is the part of the story the market had been paying a premium for. The close, down 1.9% on a rising tape, says the guide mattered more on day one.

The second and third days: The recovery to $103.70 by Friday, on a falling S&P, suggests the market concluded the guide cut was narrow and that the EPS line was protected. A stock that had already fallen 18% year to date had priced a good deal of disappointment, and a cut concentrated in two businesses with named causes did not justify a further de-rating. Several Street price targets came down, but ratings largely held.

Owning the arc: We upgraded in January at $108.61, held through a trough near $89 into the Q2 print, and watched the July beat-and-raise take the stock to $98.83. At $103.70 the stock sits about 4.5% below our upgrade price after nine months, while the S&P 500 was up 12.7% this year going into the print. That is an underperforming call so far, and the CGM reset weakens one of the reasons we made it. The spin and the operational acceleration strengthen others.

Street Perspective

Debate: Is the CGM Slowdown a Pricing Pause or the Start of Commoditization?

Bull view: Abbott is choosing to defend 50–70% international share with modest price adjustments, the U.S. is still growing near 10%, Libre Duo launches in December, a major U.S. formulary flips on January 1, and type-2 Medicare coverage would re-accelerate the business without being in anyone's numbers. This is a few quarters of digestion, not a change in the franchise.

Bear view: When the share leader in a fast-growing category starts cutting price before a reimbursement catalyst, it is a sign that competitive intensity has arrived, and CGM is following the path of every high-margin consumable that attracts new entrants. Low-to-mid-single-digit growth for "the next few quarters" may become the new normal outside the U.S.

Our take: The bear case has the better of the argument for 2026–2027. Management's own language (pricing actions over "the next few quarters") goes beyond a one-quarter adjustment, and the international business is where most CGM volume sits. We do not think the franchise is broken: the U.S. is healthy, share is being defended, and the cost base gives Abbott room to compete. But we no longer assume double-digit CGM growth, and a type-2 coverage decision is now the catalyst needed to restore it.

Debate: Does the Nutrition Spin Unlock Value or Just Move the Problem?

Bull view: Removing a slower, lower-margin, litigation-exposed consumer business leaves a ~$42B medtech, diagnostics and branded-generics company growing 50–100bp faster with gross margin more than 200bp higher, which deserves a peer-level multiple. Shareholders also keep a growing, S&P 500-eligible pure-play nutrition company, and the remaining company receives a debt-funded cash distribution.

Bear view: The spin is 14 months away, carries stranded costs and one-time charges, and leaves open whether the remaining company keeps the NEC liability. If it does, the remaining company keeps the overhang, and investors have to wait until late 2027 for value that may already be reflected in a sum-of-the-parts.

Our take: Lean bull. The strategic logic is sound, and a remaining company with a better growth and margin profile is easier to value. The liability allocation is the hinge, and the Form 10 will settle it. The spin is a reason to own the stock into 2027, not a reason to pay up for it today.

Debate: Is ABT Dead Money Until the January Guide?

Bull view: At ~18.8x the 2026 midpoint and ~17x 2027, with EPS guidance held, a 2.4% yield, an 8% Q4 sales exit and a spin catalyst, the stock prices in more disappointment than the business is producing. A deliberately low 2027 guide sets up a year of beats and raises.

Bear view: Management just told investors 2027 sales will start near 6% and would not commit to double-digit EPS growth. The stock has fallen on every sales miss this year, and with no reimbursement catalyst dated, there is little to re-rate it before the first 2027 raise.

Our take: Split. The near-term path is probably range-bound until January, and the bears are right that the catalyst calendar is thin before then. Over a 12-month horizon, a beatable 2027 guide, a growing nutrition business heading for a spin and a below-average multiple give us more upside than downside, which is the bar for Outperform. Conviction is lower because the timeline is longer.

Debate: Is EP Losing Momentum or Just Changing Products?

Bull view: U.S. EP ex-LAA grew above 20% and Europe grew 25%; TactiFlex Duo arrived early, Volt is in full release and Japan opens in Q4. The LAA drag is a product-transition air pocket that ends when Amulet 360 reaches the U.S.

Bear view: The LAA closure market has slowed for the category leader as well, and a market slowdown is not fixed by a better device. Cutting Q4 EP to about 20% from about 25% shows the segment is more exposed than the ablation numbers suggest.

Our take: Bull on ablation, neutral on LAA. The PFA share gains are the larger and more durable driver, and the LAA pause is timing. Whether the LAA category itself re-accelerates will depend on the outcome data both leaders are funding, which is a 2027–2028 question.

Model & Valuation Framework

Valuation framework: At the $103.70 close on October 23, Abbott trades at about 18.8x the $5.525 FY2026 midpoint and about 17.3x our ~$6.00 FY2027 estimate, with a $2.52 annualized dividend yielding about 2.4%. That is below the franchise's own multi-year range in the low-to-mid 20s and below large-cap medtech peers, even though the remaining company after the spin will have a better growth and margin profile than today's Abbott. Our base-case target of ~$114 (≈19x FY2027) sits about 10% above the Friday close, roughly 12% including the dividend; the bull case (~$132) is about 27% above and the bear case (~$90) about 13% below. The up-to-down skew has narrowed to roughly 2:1 from 3:1 in July.

Why we cut the target but keep the rating: The lower 2027 estimate and the slower CGM line justify a lower target, and the guide cut extends the time it will take the market to pay for the thesis. But the downgrade triggers we set in July were specific: a Q3 that decelerated, nutrition still negative, or a multiple in the low 20s ahead of the fundamentals. None occurred. Q3 accelerated, nutrition turned positive and the multiple (about 19x the FY2026 midpoint) is only modestly above the roughly 18x it reached after the Q2 rally. The spin adds a catalyst we did not have in July.

What would move us to Hold: Q4 comparable growth falling short of the ~8% exit (a second consecutive sales shortfall), a 2027 EPS guide below high-single-digit growth, evidence that CGM price competition is spreading to the U.S., or confirmation that the remaining company keeps the full NEC liability without an offsetting resolution. What would move us to Underperform: CGM share loss despite the price concessions, a reset of the organic growth rate below 5%, or a derailed separation.

Thesis Scorecard Post-Earnings

We score this quarter against the standing thesis. The commitments we set in July were: the H2 comparable ramp (Q3 stepping toward the full-year path), nutrition reaching a positive comparable print by Q4, CGM cadence and the type-2 Medicare decision, Core Lab acceleration as China eased, U.S. Structural Heart reaching mid-to-high single digits by Q4, the U.S. ramp of the new PFA catheter, gross margin holding near 58%, and stable diagnostic-volume data. The scorecard:

Overall: The thesis is intact but narrower than in July. The operating commitments we set were mostly met: the quarter accelerated, nutrition turned positive early, diagnostics broadened, EP accelerated and margins expanded. The miss is the one that matters for the multiple. CGM growth is slowing on pricing, the full-year sales guide came down, and management is resetting 2027 expectations. The Nutrition spin is a genuine new positive that partly offsets the CGM damage by giving the remaining company a cleaner growth and margin profile. On balance the thesis weakened modestly; the stock did not.

Action: Maintain Outperform with lower conviction; trim the base target to ~$114. The next checkpoints are the Q4 exit rate near 8%, the January 2027 guide, the CGM pricing effect on margins, and the NEC allocation in the spin filings.

Bottom Line: Narrower Thesis, Same Call

Rating decision: We maintain Outperform on Abbott, with lower conviction and a base target cut to ~$114 from ~$119. The quarter met the operating tests we set in July. Comparable growth accelerated to 7.0%, nutrition turned positive a quarter ahead of schedule, diagnostics broadened, and margins and EPS landed on plan. The guide cut was the risk we flagged, and we were right to flag it. Its cause was concentrated in LAA timing and CGM pricing, not in a broad slowdown.

The CGM change is the reason conviction comes down. Our thesis treated Libre as a structurally double-digit growth engine that justified a premium multiple, and management has now told us international pricing will hold it to low-to-mid single digits for several quarters. That moves the Libre pillar to at risk, and it means a re-rating needs either the type-2 Medicare decision or a clean 2027 beat-and-raise cycle. The spin is the offset: it removes the segment that has caused most of our bear points over five quarters and leaves a faster, higher-margin company that should command a better multiple once the liability question is settled.

At ~17x our 2027 estimate, with a 2.4% yield and EPS guidance intact, the stock offers more upside than downside over twelve months. We expect the path to be slower than we argued in July, and we will judge the call on the Q4 exit rate and the January guide.

What we are watching into Q4 2026 (January):